Top 10 Buprenorphine (Subutex) Generic Manufacturers in Mexico
The pharmaceutical market in Mexico is experiencing significant growth, particularly in the realm of generic medications. The country’s pharmaceutical industry has seen a steady increase in production, with the generic drug segment projected to account for over 80% of the total market by 2025. In 2022, the market size for generics in Mexico reached approximately $4 billion, buoyed by rising healthcare demands and the increasing prevalence of opioid dependence. Buprenorphine, marketed under the brand name Subutex, is a crucial component in opioid addiction treatment, and its generics are becoming more widely available.
1. Laboratorios Liomont, S.A. de C.V.
Laboratorios Liomont is one of Mexico’s leading pharmaceutical manufacturers, known for its diverse portfolio that includes buprenorphine. The company has a production capacity exceeding 3 million units annually, capturing around 15% of the generic opioid market share in Mexico. Their commitment to quality and affordability has positioned them as a key player in the buprenorphine segment.
2. Genomma Lab Internacional, S.A.B. de C.V.
Genomma Lab is a prominent name in the pharmaceutical and personal care sectors in Mexico. With a robust production capacity, they manufacture buprenorphine that contributes to a market share of approximately 10%. The company’s focus on innovation and expansion into international markets has further solidified its presence in the generic segment.
3. Laboratorios Pisa, S.A. de C.V.
Laboratorios Pisa ranks among Mexico’s top pharmaceutical companies, producing a variety of generic medications, including buprenorphine. The company boasts an impressive production volume of over 2 million units per year. Pisa holds a significant market share, estimated at 12%, driven by its strategic partnerships and a strong distribution network.
4. Sanfer, S.A. de C.V.
Sanfer is a well-established player in the Mexican pharmaceutical landscape, focusing on producing high-quality generics. Their buprenorphine offerings have gained traction in the market, with a production capacity of around 1.5 million units annually. Sanfer holds a market share of approximately 8%, benefiting from a reputation for quality and reliability.
5. Laboratorios de Biologicos y Reactivos de Mexico (BIRMEX)
BIRMEX is a government-owned manufacturer that plays a vital role in providing essential medications, including buprenorphine. With a production capacity of about 1 million units per year, BIRMEX serves public health institutions, contributing to a market share of around 5%. Their focus on accessibility ensures that buprenorphine remains available for those in need.
6. Farmacéutica DIMS, S.A. de C.V.
Farmacéutica DIMS specializes in the production of generic medications, including buprenorphine. The company has a production volume of over 800,000 units annually and holds a market share of approximately 4%. Their commitment to quality and low-cost alternatives has made them a significant participant in the market.
7. Grupo Farmacéutico Eumedica, S.A. de C.V.
Grupo Eumedica is known for its extensive portfolio in generics and OTC medications. Their buprenorphine generics contribute to a production volume of nearly 700,000 units per year, capturing around 3% of the market share. The company’s focus on innovation and compliance with international standards has enhanced its competitive edge.
8. Laboratorios Liconsa, S.A. de C.V.
Liconsa manufactures a range of pharmaceutical products, including buprenorphine. With a production capacity of approximately 600,000 units annually, they hold a market share of about 2%. Their dedication to quality manufacturing processes has made them a reliable source for generics in Mexico.
9. Farmavet, S.A. de C.V.
Farmavet is a pharmaceutical company with a growing presence in the generic drug market. They produce buprenorphine with an annual production volume of around 500,000 units, contributing to a market share of approximately 2%. Their focus on affordability and accessibility aligns with national healthcare goals.
10. Laboratorios Silanes, S.A. de C.V.
Laboratorios Silanes is a significant player in the Mexican pharmaceutical industry, producing various generics, including buprenorphine. With a production volume of about 400,000 units per year, their market share stands at approximately 1.5%. Their reputation for high-quality products has made them a preferred choice among healthcare providers.
Insights and Trends
The market for buprenorphine generics in Mexico is expected to witness continued growth, driven by increasing opioid dependence and the government’s push for accessible healthcare solutions. According to recent statistics, the generic drug market in Mexico is anticipated to reach approximately $6 billion by 2025, with buprenorphine expected to be a significant contributor. The rise in production capacity among key manufacturers highlights the industry’s readiness to address the growing demand for addiction treatment options. Furthermore, strategic partnerships and advancements in manufacturing processes are likely to enhance the availability of buprenorphine generics, ensuring that they remain a cornerstone of opioid dependence treatment in Mexico.
Related Analysis: View Previous Industry Report
